Polydatin inhibits growth of lung cancer cells by inducing apoptosis and causing cell cycle arrest

Oncology Letters

Volumn 7, Issue 1, 2014, Pages 295-301

  Zhang, Yusong ^a,b   Zhuang, Zhixiang ^a   Meng, Qinghui ^c   Jiao, Yang ^b   Xu, Jiaying ^b   Fan, Saijun ^b  

^a THE SECOND AFFILIATED HOSPITAL OF SOOCHOW UNIVERSITY   (China)

^b MEDICAL COLLEGE OF SOOCHOW UNIVERSITY   (China)

^c GEORGETOWN UNIVERSITY   (United States)

Author keywords

Apoptosis; Cyclin D1; Lung cancer; Polydatin

Indexed keywords

CYCLIN D1; PLANT MEDICINAL PRODUCT; POLYDATIN; PROTEIN BAX; PROTEIN BCL 2; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CELL CYCLE ARREST; CELL CYCLE S PHASE; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; DRUG DOSE COMPARISON; FLOW CYTOMETRY; GROWTH INHIBITION; HUMAN; HUMAN CELL; LUNG CANCER; PROTEIN EXPRESSION; WESTERN BLOTTING;

EID: 84888409477     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2013.1696     Document Type: Article

References (43)

1. Spiro SG, Tanner NT, Silvestri GA, et al: Lung cancer: progress in diagnosis, staging and therapy. Respirology 15: 44-50, 2010.
2. Stinchcombe TE, Fried D, Morris DE and Socinski MA: Combined modality therapy for stage III non-small cell lung cancer. Oncologist 11: 809-823, 2006.
3. Luan J, Duan H, Liu Q, Yagasaki K and Zhang G: Inhibitory effects of norcantharidin against human lung cancer cell growth and migration. Cytotechnology 62: 349-355, 2010.
4. Newman DJ and Cragg GM: Natural products as sources of new drugs over the last 25 years. J Nat Prod 70: 461-477, 2007.
5. Cragg GM and Newman DJ: Plants as a source of anti-cancer agents. J Ethnopharmacol 100: 72-79, 2005.
6. Gordaliza M: Natural products as leads to anticancer drugs. Clin Transl Oncol 9: 767-776, 2007.
7. Zhao KS, Jin C, Huang X, et al: The mechanism of Polydatin in shock treatment. Clin Hemorheol Microcirc 29: 211-217, 2003.
8. Wang X, Song R, Chen Y, Zhao M and Zhao KS: Polydatin-a new mitochondria protector for acute severe hemorrhagic shock treatment. Expert Opin Investig Drugs 22: 169-179, 2013.
9. Wang X, Song R, Bian HN, Brunk UT, Zhao M and Zhao KS: Polydatin, a natural polyphenol, protects arterial smooth muscle cells against mitochondrial dysfunction and lysosomal destabilization following hemorrhagic shock. Am J Physiol Regul Integr Comp Physiol 302: R805-R814, 2012.
10. Cheng Y, Zhang HT, Sun L, et al: Involvement of cell adhesion molecules in polydatin protection of brain tissues from ischemia-reperfusion injury. Brain Res 1110: 193-200, 2006.
11. Miao Q, Wang S, Miao S, Wang J, Xie Y and Yang Q: Cardioprotective effect of polydatin against ischemia/reperfusion injury: roles of protein kinase C and mito K(ATP) activation. Phytomedicine 19: 8-12, 2011.
12. Gao JP, Chen CX, Gu WL, Wu Q, Wang Y and Lü J: Effects of polydatin on attenuating ventricular remodeling in isoproterenol-induced mouse and pressure-overload rat models. Fitoterapia 81: 953-960, 2010.
13. Indraccolo U and Barbieri F: Effect of palmitoylethanolamide-polydatin combination on chronic pelvic pain associated with endometriosis: preliminary observations. Eur J Obstet Gynecol Reprod Biol 150: 76-79, 2010.
14. Fan S, Wang JA, Yuan RQ, et al: BRCA1 as a potential human prostate tumor suppressor: modulation of proliferation, damage responses and expression of cell regulatory proteins. Oncogene 16: 3069-3082, 1998.
15. Vermes I, Haanen C, Steffens-Nakken H and Reutelingsperger C: A novel assay for apoptosis. Flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled Annexin V. J Immunol Methods 184: 39-51, 1995.
16. Fan S, Gao M, Meng Q, et al: Role of NF-kappaB signaling in hepatocyte growth factor/scatter factor-mediated cell protection. Oncogene 24: 1749-1766, 2005.
17. Xu JY, Meng QH, Chong Y, et al: Sanguinarine inhibits growth of human cervical cancer cells through the induction of apoptosis. Oncol Rep 28: 2264-2270, 2012.
18. Hollman PC, de Vries JH, van LSD, Mengelers MJ and Katan MB: Absorption of dietary quercetin glycosides and quercetin in healthy ileostomy volunteers. Am J Clin Nutr 62: 1276-1282, 1995.
19. Paganga G and Rice-Evans CA: The identification of flavonoids as glycosides in human plasma. FEBS Lett 401: 78-82, 1997.
20. Regev-Shoshani G, Shoseyov O, Bilkis I and Kerem Z: Glycosylation of resveratrol protects it from enzymic oxidation. Biochem J 374: 157-163, 2003.
21. Krasnow MN and Murphy TM: Polyphenol glucosylating activity in cell suspensions of grape (Vitis vinifera). J Agric Food Chem 52: 3467-3472, 2004.
22. Jang M, Cai L, Udeani GO, et al: Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science 275: 218-220, 1997.
23. Joe AK, Liu H, Suzui M, Vural ME, Xiao D and Weinstein IB: Resveratrol induces growth inhibition, S-phase arrest, apoptosis, and changes in biomarker expression in several human cancer cell lines. Clin Cancer Res 8: 893-903, 2002.
24. Rezk YA, Balulad SS, Keller RS and Bennett JA: Use of resveratrol to improve the effectiveness of cisplatin and doxorubicin: study in human gynecologic cancer cell lines and in rodent heart. Am J Obstet Gynecol 194: e23-e26, 2006.
25. Liu PL, Tsai JR, Charles AL, et al: Resveratrol inhibits human lung adenocarcinoma cell metastasis by suppressing heme oxygenase 1-mediated nuclear factor-kappaB pathway and subsequently downregulating expression of matrix metalloproteinases. Mol Nutr Food Res 54 (Suppl 2): S196-S204, 2010.
26. Shibata MA, Akao Y, Shibata E, et al: Vaticanol C, a novel resveratrol tetramer, reduces lymph node and lung metastases of mouse mammary carcinoma carrying p53 mutation. Cancer Chemother Pharmacol 60: 681-691, 2007.
27. Liu HS, Pan CE, Yang W and Liu XM: Antitumor and immunomodulatory activity of resveratrol on experimentally implanted tumor of H22 in Balb/c mice. World J Gastroenterol 9: 1474-1476, 2003.
28. Zhou HB, Chen JJ, Wang WX, Cai JT and Du Q: Anticancer activity of resveratrol on implanted human primary gastric carcinoma cells in nude mice. World J Gastroenterol 11: 280-284, 2005.
29. Pan MH, Gao JH, Lai CS, et al: Antitumor activity of 3,5,4'-trimethoxystilbene in COLO 205 cells and xenografts in SCID mice. Mol Carcinog 47: 184-196, 2008.
30. Li T, Fan GX, Wang W, Li T and Yuan YK: Resveratrol induces apoptosis, influences IL-6 and exerts immunomodulatory effect on mouse lymphocytic leukemia both in vitro and in vivo. Int Immunopharmacol 7: 1221-1231, 2007.
31. Chen JC, Chen Y, Lin JH, Wu JM and Tseng SH: Resveratrol suppresses angiogenesis in gliomas: evaluation by color Doppler ultrasound. Anticancer Res 26: 1237-1245, 2006.
32. Wyllie AH: Apoptosis: an overview. Br Med Bull 53: 451-465, 1997.
33. Neto CC, Amoroso JW and Liberty AM: Anticancer activities of cranberry phytochemicals: an update. Mol Nutr Food Res 52 (Suppl 1): S18-S27, 2008.
34. Kaur M and Agarwal R: Transcription factors: molecular targets for prostate cancer intervention by phytochemicals. Curr Cancer Drug Targets 7: 355-367, 2007.
35. Yang J, Liu X, Bhalla K, et al: Prevention of apoptosis by Bcl-2: release of cytochrome c from mitochondria blocked. Science 275: 1129-1132, 1997.
36. Kluck RM, Bossy-Wetzel E, Green DR and Newmeyer DD: The release of cytochrome c from mitochondria: a primary site for Bcl-2 regulation of apoptosis. Science 275: 1132-1136, 1997.
37. Graña X and Reddy EP: Cell cycle control in mammalian cells: role of cyclins, cyclin dependent kinases (CDKs), growth suppressor genes and cyclin-dependent kinase inhibitors (CKIs). Oncogene 11: 211-219, 1995.
38. Pavletich NP: Mechanisms of cyclin-dependent kinase regulation: structures of Cdks, their cyclin activators, and Cip and INK4 inhibitors. J Mol Biol 287: 821-828, 1999.
39. Alao JP: The regulation of cyclin D1 degradation: roles in cancer development and the potential for therapeutic invention. Mol Cancer 6: 24, 2007.
40. Gillett C, Smith P, Gregory W, et al: Cyclin D1 and prognosis in human breast cancer. Int J Cancer 69: 92-99, 1996.
41. Hall M and Peters G: Genetic alterations of cyclins, cyclin-dependent kinases, and Cdk inhibitors in human cancer. Adv Cancer Res 68: 67-108, 1996.
42. Molenaar JJ, Ebus ME, Koster J, et al: Cyclin D1 and CDK4 activity contribute to the undifferentiated phenotype in neuroblastoma. Cancer Res 68: 2599-2609, 2008.
43. Yang K, Hitomi M and Stacey DW: Variations in cyclin D1 levels through the cell cycle determine the proliferative fate of a cell. Cell Div 1: 32, 2006.